Compare Stocks: KZR, ORGO, KROS, and TNXP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KROS Keros Therapeutics	$11.08 +0.5%	$10.78	$9.69 ▼ $22.55	$218.69M	0.99	223,647 shs	179,962 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs
ORGO Organogenesis	$1.72 -1.1%	$2.23	$1.54 ▼ $7.08	$223.89M	1.34	907,632 shs	638,390 shs
TNXP Tonix Pharmaceuticals	$14.10 +3.8%	$12.02	$9.40 ▼ $31.55	$233.08M	1.69	490,186 shs	568,746 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KROS Keros Therapeutics	+0.45%	+2.78%	+10.03%	+5.02%	-27.15%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	0.00%	+84.56%
ORGO Organogenesis	-1.15%	+2.99%	-27.43%	-23.21%	-66.60%
TNXP Tonix Pharmaceuticals	+3.75%	+13.25%	+40.86%	+20.31%	-52.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KROS Keros Therapeutics	$11.08 +0.5%	$10.78	$9.69 ▼ $22.55	$218.69M	0.99	223,647 shs	179,962 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs
ORGO Organogenesis	$1.72 -1.1%	$2.23	$1.54 ▼ $7.08	$223.89M	1.34	907,632 shs	638,390 shs
TNXP Tonix Pharmaceuticals	$14.10 +3.8%	$12.02	$9.40 ▼ $31.55	$233.08M	1.69	490,186 shs	568,746 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KROS Keros Therapeutics	+0.45%	+2.78%	+10.03%	+5.02%	-27.15%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	0.00%	+84.56%
ORGO Organogenesis	-1.15%	+2.99%	-27.43%	-23.21%	-66.60%
TNXP Tonix Pharmaceuticals	+3.75%	+13.25%	+40.86%	+20.31%	-52.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KROS Keros Therapeutics	2.33	Hold	$20.50	85.02% Upside
KZR Kezar Life Sciences	1.60	Reduce	$6.00	-17.70% Downside
ORGO Organogenesis	1.67	Reduce	$4.33	151.94% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	73.76% Upside

Current Analyst Ratings Breakdown

Latest KZR, ORGO, KROS, and TNXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/7/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	ORGO Organogenesis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$3.00 ➝ $2.00
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00
8/4/2026	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/4/2026	KROS Keros Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$30.00 ➝ $23.00
7/29/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KROS Keros Therapeutics	$244.06M	0.90	$4.54 per share	2.44	$15.51 per share	0.71
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	$9.57 per share	N/A
ORGO Organogenesis	$564.17M	0.39	$0.64 per share	2.69	$2.36 per share	0.73
TNXP Tonix Pharmaceuticals	$13.11M	18.45	N/A	N/A	$19.17 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
KZR Kezar Life Sciences	-$56.03M	-$6.17	N/A	N/A	N/A	N/A	-55.42%	-47.87%	N/A
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest KZR, ORGO, KROS, and TNXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KROS Keros Therapeutics	N/A	21.96	21.96
KZR Kezar Life Sciences	N/A	11.52	11.52
ORGO Organogenesis	0.07	3.52	3.00
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KROS Keros Therapeutics	71.56%
KZR Kezar Life Sciences	67.90%
ORGO Organogenesis	49.57%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
KROS Keros Therapeutics	12.60%
KZR Kezar Life Sciences	10.40%
ORGO Organogenesis	18.80%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable
KZR Kezar Life Sciences	60	7.39 million	6.70 million	Not Optionable
ORGO Organogenesis	950	128.68 million	104.48 million	Optionable
TNXP Tonix Pharmaceuticals	50	17.15 million	16.81 million	Not Optionable

KZR, ORGO, KROS, and TNXP Headlines

Recent News About These Companies

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

25 minutes ago | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31 at 9:06 AM | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

August 29 at 1:24 AM | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen

August 29 at 1:23 AM | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock

August 24, 2026 | marketbeat.com

Tonix Pharma Names CEO Seth Lederman Interim CMO

August 18, 2026 | tipranks.com

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

August 18, 2026 | marketbeat.com

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

August 17, 2026 | fool.com

Tonix Pharmaceuticals Earnings Call Highlights Surging TONMYA Momentum

August 12, 2026 | theglobeandmail.com

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

August 11, 2026 | tipranks.com

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

August 10, 2026 | markets.businessinsider.com

Tonix outlines TNX-4800 Phase II with ~3,300 participants while scaling TONMYA to ~150 reps by September

August 10, 2026 | seekingalpha.com

Tonix Pharmaceuticals Holding C (TNXP) Q2 FY2026 earnings call transcript

August 10, 2026 | finance.yahoo.com

Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal?

August 10, 2026 | kalkinemedia.comK

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

August 10, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Q2 Earnings Call Highlights

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results

August 10, 2026 | marketbeat.com

Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million

August 10, 2026 | quiverquant.comQ

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

August 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KZR, ORGO, KROS, and TNXP Company Descriptions

Keros Therapeutics NASDAQ:KROS

$11.08 +0.05 (+0.45%)

As of 08/31/2026 04:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Kezar Life Sciences NASDAQ:KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organogenesis NASDAQ:ORGO

$1.72 -0.02 (-1.15%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$1.75 +0.03 (+1.69%)

As of 04:09 AM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Tonix Pharmaceuticals NASDAQ:TNXP

$14.10 +0.51 (+3.75%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$14.00 -0.10 (-0.74%)

As of 04:02 AM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, ORGO, KROS, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, ORGO, KROS, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, ORGO, KROS, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KZR, ORGO, KROS, and TNXP Company Descriptions

Keros Therapeutics NASDAQ:KROS

Kezar Life Sciences NASDAQ:KZR

Organogenesis NASDAQ:ORGO

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, ORGO, KROS, and TNXP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, ORGO, KROS, and TNXP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, ORGO, KROS, and TNXP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KZR, ORGO, KROS, and TNXP Company Descriptions

Keros Therapeutics NASDAQ:KROS

Kezar Life Sciences NASDAQ:KZR

Organogenesis NASDAQ:ORGO

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools